Overview

Advancing Transplantation Outcomes in Children

Status:
Recruiting
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF). Two hundred participants will be randomized (1:1) to one of two groups within 24 hours following the transplant procedure. The duration of the study from time of transplant to the primary endpoint is 12-24 months.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Abatacept
Antilymphocyte Serum
Mycophenolic Acid
Sirolimus
Tacrolimus